Assess whether to resubmit, meet, or pause the program (48475e)

SITUATION An AdCom briefing document that overstates subgroup findings put disproportionate reporting signal workbook in front of clinical-development physician in a biologics company planning a biosimilar pathway. This Pharma & Life Sciences / Clinical and Evidence Strategy close is to resubmit, meet, or from disproportionate reporting signal workbook, and the live options are To resubmit, meet,, Pause the program.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Disproportionate reporting signal workbook reads as To resubmit, meet, once an AdCom briefing document that overstates subgroup findings is lined up to the same Pharma & Life Sciences population. 2. Disproportionate reporting signal workbook is closer to Pause the program after an AdCom briefing document that overstates subgroup findings; To resubmit, meet, would over-claim this Clinical and Evidence Strategy extract. 3. A dual reading is still live in disproportionate reporting signal workbook for clinical-development physician in a biologics company planning a biosimilar pathway. 4. Disproportionate reporting signal workbook is missing the fact clinical-development physician needs after an AdCom briefing document that overstates subgroup findings; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 3. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for clinical-development physician.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for clinical-development physician - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Clinical and Evidence Strategy finding in disproportionate reporting signal workbook that a second reviewer can re-perform - Missing page in disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings, if any